AMAG Pharmaceuticals
AMAG
AMAG was delisted on the 13th of November, 2020.
113 hedge funds and large institutions have $348M invested in AMAG Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 24 increasing their positions, 53 reducing their positions, and 14 closing their positions.
19% more capital invested
Capital invested by funds: $294M → $348M (+$54.6M)
1% more call options, than puts
Call options by funds: $4.67M | Put options by funds: $4.6M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 119 → 113 (-6)
43% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 14
55% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 53
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$3.39M |
| 2 |
Morgan Stanley
New York
|
+$1.97M |
| 3 |
D.E. Shaw & Co
New York
|
+$1.1M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$839K |
| 5 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$421K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.99M |
| 2 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$2.27M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.97M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.35M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.28M |
AMAG Hedge Fund Activity: Q3 2020 in Review
113 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in AMAG Pharmaceuticals (AMAG) for Q3 2020, worth a combined $348M — up 19% from $294M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of AMAG and 8 opened new positions — a net loss of 6 holders — while 53 trimmed existing stakes and 24 added.
The largest buyer was Goldman Sachs, adding an estimated $3.39M. The largest seller was BlackRock, cutting an estimated $2.99M.
- 113 institutional investors held AMAG Pharmaceuticals (AMAG) as of Q3 2020, down from 119 in Q2 2020.
- Funds reported $348M of AMAG Pharmaceuticals stock for Q3 2020, up 19% quarter-over-quarter.
- 8 funds opened new AMAG Pharmaceuticals positions in Q3 2020 and 14 closed out, a net change of -6 holders.
- The largest AMAG Pharmaceuticals buyer in Q3 2020 was Goldman Sachs, an estimated $3.39M added.
- The largest AMAG Pharmaceuticals seller in Q3 2020 was BlackRock, an estimated $2.99M sold.
Based on aggregated 13F filings for Q3 2020.